Amgen Inc Stock Current Valuation
| AMG Stock | EUR 251.65 1.20 0.47% |
Valuation analysis of Amgen Inc helps investors to measure Amgen's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Amgen's price fluctuation is out of control at this time. Calculation of the real value of Amgen Inc is based on 3 months time horizon. Increasing Amgen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Amgen's intrinsic value may or may not be the same as its current market price of 251.65, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 251.65 | Real 0.0 | Hype 0.0 |
The intrinsic value of Amgen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Amgen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Amgen Inc helps investors to forecast how Amgen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Amgen more accurately as focusing exclusively on Amgen's fundamentals will not take into account other important factors: Amgen Inc Company Current Valuation Analysis
Amgen's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Amgen Current Valuation | 163.09 B |
Most of Amgen's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amgen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Amgen Inc has a Current Valuation of 163.09 B. This is much higher than that of the Other sector and significantly higher than that of the Other industry. The current valuation for all Germany stocks is notably lower than that of the firm.
Amgen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amgen's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amgen could also be used in its relative valuation, which is a method of valuing Amgen by comparing valuation metrics of similar companies.Amgen is currently under evaluation in current valuation category among its peers.
Amgen Fundamentals
| Current Valuation | 163.09 B | |||
| Price To Book | 39.61 X | |||
| Price To Sales | 5.64 X | |||
| Revenue | 26.32 B | |||
| EBITDA | 12.17 B | |||
| Net Income | 6.55 B | |||
| Total Debt | 37.35 B | |||
| Cash Flow From Operations | 9.72 B | |||
| Price To Earnings To Growth | 1.55 X | |||
| Number Of Employees | 20 | |||
| Market Capitalization | 105.18 B | |||
| Total Asset | 65.12 B | |||
| Z Score | 1.2 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 65.12 B | |||
| Last Dividend Paid | 1.6 |
About Amgen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amgen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amgen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amgen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Amgen Stock Analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.